USP39 and B-cell non-Hodgkin lymphoma: Because the spliceosome component of USP39 has a role in B-cell development and in controlling the rearrangement of immunoglobulin genes, targeting USP39 could represent a promising therapeutic strategy for treating B-cell lymphoma (Ruan et al., 2022).